TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Fourteen standing departments. Each has its own editor, its own colour and its own typographic register — the analytical departments run a tighter measure and mono figure captions; Dispatches sets two columns on a wide screen; The Back Page is one wide serif column.
224 pieces
Incretin pharmacology reported from the primary literature: receptor selectivity and bias, pharmacokinetics and steady state, the difference between a dual agonist and a co-formulation, and the mechanisms behind the effects patients notice first.
1,327 pieces
Reporting on how research peptides are actually made and moved: synthesis houses, resin and reagent sourcing, fill-finish, packaging, freight, customs, and the twenty companies whose names appear most often on the label. Our vendor dossiers live here.
516 pieces
The trial programmes — STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH and the outcome studies that followed — read as designs rather than headlines. We report the estimand, the comparator, the withdrawal rate and the population, every time.
500 pieces
How purity, identity and content are measured, by whom, on what instrument, under what method — and what a certificate of analysis can and cannot support. Coverage of the four independent testing services: Janoshik, Medutest, PeptideMeter and VendorInvestigate.
537 pieces
The legal picture, reported from dockets and enforcement records rather than summaries: 503A and 503B, shortage listings, "research use only", personal-importation allowances, and what an inspection observation actually means.
284 pieces
Correspondents in Latin America, East Asia and Europe on what is available, at what price, under what rule — and how quickly a formulary decision in one capital reaches a pharmacy counter in another.
491 pieces
The practical column: dose escalation and dose holding, gastrointestinal management, injection technique and unit arithmetic, body composition, and the question nobody asks until month nine — what happens when you stop. Not medical advice.
488 pieces
The economics: list price against negotiated price, the cost of goods against the cost of a prescription, prior authorisation and appeal outcomes, and the arithmetic a cash-paying patient is actually doing.
225 pieces
Closer to the bench: what a laboratory panel measures and what a change in it means, reconstitution and stability data, bioburden and endotoxin, container closure integrity, and the tests a certificate usually omits.
0 pieces
The Journal’s running correction log, plus reporting on how errors travel. Corrections are published in full, dated, linked to the piece they amend, and never quietly edited into the original.
283 pieces
When a compounding operation, a distributor or a testing service stops trading, we write it up: what it did, what it was worth to its customers, what closed it, and what happened to the people holding open orders. We distinguish a business that failed from one that was closed.
0 pieces
The correspondence column. Roughly a thousand readers write to the Journal each month; a fraction are printed here with the writer’s initial and city, and the desk replies where a reply is owed. Factual challenges go to the standards editor first.
225 pieces
For readers arriving new: what these drugs are, how they are given, what the words on the label mean, and how to tell a measurement from a marketing claim. Written to be read once.
0 pieces
One essay per issue on the culture of medicines rather than their chemistry — what we expect of a drug that works, what we forgive it, and what a treatment changes about the people who take it.